[go: up one dir, main page]

WO2013016720A3 - Novel substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases - Google Patents

Novel substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases Download PDF

Info

Publication number
WO2013016720A3
WO2013016720A3 PCT/US2012/048741 US2012048741W WO2013016720A3 WO 2013016720 A3 WO2013016720 A3 WO 2013016720A3 US 2012048741 W US2012048741 W US 2012048741W WO 2013016720 A3 WO2013016720 A3 WO 2013016720A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein kinase
diseases
biarylheterocycle
cancer
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/048741
Other languages
French (fr)
Other versions
WO2013016720A2 (en
Inventor
Magnus Pfahl
F. Javier PIEDRAFITA
Laxman Rao Cilamkoti VENKAT
Venugopal Rao VEERAMANENI
Bhaskar Venepalli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GERINDA THERAPEUTICS Inc
Original Assignee
GERINDA THERAPEUTICS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GERINDA THERAPEUTICS Inc filed Critical GERINDA THERAPEUTICS Inc
Publication of WO2013016720A2 publication Critical patent/WO2013016720A2/en
Publication of WO2013016720A3 publication Critical patent/WO2013016720A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a new patentable class of substituted benzoxazole derivative compounds that exhibit protein kinase (PK) inhibition activity or modulating ability, as well as compositions and methods of using such compounds, for example, to prevent or treat various diseases and disorders in human and non-human animals.
PCT/US2012/048741 2011-07-28 2012-07-28 Novel substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases Ceased WO2013016720A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161512882P 2011-07-28 2011-07-28
US61/512,882 2011-07-28

Publications (2)

Publication Number Publication Date
WO2013016720A2 WO2013016720A2 (en) 2013-01-31
WO2013016720A3 true WO2013016720A3 (en) 2013-03-28

Family

ID=47601783

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/048741 Ceased WO2013016720A2 (en) 2011-07-28 2012-07-28 Novel substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases

Country Status (1)

Country Link
WO (1) WO2013016720A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3521291A1 (en) 2010-05-20 2019-08-07 Array Biopharma, Inc. Macrocyclic compounds as trk kinase inhibitors
KR20180041135A (en) 2015-07-16 2018-04-23 어레이 바이오파마 인크. A pyrazolo [1,5-a] pyridine compound substituted as a RET kinase inhibitor
JOP20190077A1 (en) 2016-10-10 2019-04-09 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
TWI704148B (en) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
CN110267960B (en) 2017-01-18 2022-04-26 阿雷生物药品公司 Substituted pyrazolo [1,5-a ] pyrazine compounds as RET kinase inhibitors
JOP20190213A1 (en) 2017-03-16 2019-09-16 Array Biopharma Inc Macrocyclic compounds as ros1 kinase inhibitors
TWI791053B (en) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 Crystalline forms of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and pharmaceutical composition thereof
TWI876442B (en) 2017-10-10 2025-03-11 美商絡速藥業公司 Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
TW201932464A (en) 2018-01-18 2019-08-16 美商亞雷生物製藥股份有限公司 Substituted pyrazolyl[4,3-C]pyridine compounds as RET kinase inhibitors
US11603374B2 (en) 2018-01-18 2023-03-14 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
WO2019143991A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS
WO2020055672A1 (en) 2018-09-10 2020-03-19 Array Biopharma Inc. Fused heterocyclic compounds as ret kinase inhibitors
CN116253686B (en) * 2022-12-09 2023-11-17 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) Aminobenzimidazole benzamide derivatives and their applications

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2262932C2 (en) * 2000-12-15 2005-10-27 Вертекс Фармасьютикалз Инкорпорейтед Inhibitors of bacterial gyrase and their applying
WO2009156966A1 (en) * 2008-06-25 2009-12-30 Ranbaxy Laboratories Limited Benzothiazoles and aza-analogues thereof use as antibacterial agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2262932C2 (en) * 2000-12-15 2005-10-27 Вертекс Фармасьютикалз Инкорпорейтед Inhibitors of bacterial gyrase and their applying
WO2009156966A1 (en) * 2008-06-25 2009-12-30 Ranbaxy Laboratories Limited Benzothiazoles and aza-analogues thereof use as antibacterial agents

Also Published As

Publication number Publication date
WO2013016720A2 (en) 2013-01-31

Similar Documents

Publication Publication Date Title
WO2013016720A3 (en) Novel substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases
MX2014005928A (en) Heterocyclic inhibitors of glutaminase.
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
EA201490545A1 (en) COMPOUNDS AND COMPOSITIONS AS KINASE C-Kit KINASE INHIBITORS
MY167245A (en) Compounds and compositions as c-kit kinase inhibitors
TN2012000081A1 (en) Compounds and compositions as protein kinase inhibitors
WO2011014795A3 (en) Compounds and compositions as syk kinase inhibitors
WO2014031928A3 (en) Heterocyclic modulators of hif activity for treatment of disease
MX2009011951A (en) Compounds and compositions as c-kit and pdgfr kinase inhibitors.
EA201791018A1 (en) DERIVATIVES OF 6-AMINO-7-BICYCLO-7-DEAZAPURIN AS PROTECTINININASE INHIBITORS
EA201490542A1 (en) COMPOUNDS AND COMPOSITIONS AS A PDGFR KINASE INHIBITOR
MX342509B (en) Substituted indazole derivatives active as kinase inhibitors.
MX2010009207A (en) Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors.
EA201490539A1 (en) COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS
WO2014031933A3 (en) Heterocyclic modulators of hif activity for treatment of disease
EA201500182A1 (en) 4-METHYL-2,3,5,9,9b-PENTAASACYCLOPENT [a] NAFTAIL
WO2014031936A3 (en) Heterocyclic modulators of hif activity for treatment of disease
IN2015DN01151A (en)
MX2009011952A (en) Compounds and compositions as c-kit and pdgfr kinase inhibitors.
MX337849B (en) Compositions and methods for inhibition of the jak pathway.
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
EA201390520A1 (en) SUBSTITUTED COMPOUNDS PYRIDAZINCARBOXAMIDA
UA108878C2 (en) PROTEINTYROZINCINASE ACTIVITY INHIBITORS
TN2013000150A1 (en) Co-crystals and salts of ccr3-inhibitors
MX2014002343A (en) Parp inhibitors.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12818072

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12818072

Country of ref document: EP

Kind code of ref document: A2